RAPT Therapeutics Inc RAPT.OQ RAPT.O is expected to show no change in quarterly revenue when it reports results on March 5 (estimated) for the period ending December 31 2024
LSEG's mean analyst estimate for RAPT Therapeutics Inc is for a loss of 37 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for RAPT Therapeutics Inc is $4.00, above its last closing price of $1.14.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.57 | -0.56 | -0.47 | Beat | 16.7 |
Jun. 30 2024 | -0.72 | -0.72 | -0.71 | Beat | 1.4 |
Mar. 31 2024 | -0.80 | -0.81 | -0.79 | Beat | 2.3 |
Dec. 31 2023 | -0.86 | -0.86 | -0.80 | Beat | 6.8 |
Sep. 30 2023 | -0.75 | -0.75 | -0.82 | Missed | -8.9 |
Jun. 30 2023 | -0.79 | -0.78 | -0.66 | Beat | 15.6 |
Mar. 31 2023 | -0.67 | -0.68 | -0.76 | Missed | -11.8 |
Dec. 31 2022 | -0.62 | -0.65 | -0.64 | Beat | 2.1 |
This summary was machine generated March 3 at 13:37 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。